The latest news, updates and opinions on Pearson from the expert team here at MoneyWeek
Bausch Health: an ex-sinner to buy now
Features Pharmaceutical firm Bausch Health, formerly known as Valeant, is putting a dodgy past behind it.
Three laggards to buy for long-term growth
Opinion Some of the best long-term capital-growth opportunities lie in companies that have struggled over the past few years, says professional investor Ben Ritchie. Here, he picks three of his favourites.
By Ben Ritchie PublishedOpinion
The smart money is backing print – so why is Pearson flogging The Economist?
Opinion In selling The Economist, Pearson might well be flogging the wrong assets at the wrong time, says Matthew Lynn.
By Matthew Lynn PublishedOpinion